Society / Aging Society
Innovative Nano-Electronics for Neurological Disorders
Deblina Sarkar's research focuses on developing autonomous, non-surgical nano-electronic implants that can integrate with biological tissue, potentially transforming treatments for neurological disorders. Current invasive brain implants are limited to less than 1% of patients due to high costs and significant risks.
Source material: Deblina Sarkar | Autonomous and Surgery-free Nano-Electronics for Brain-Computer Symbiosis
Summary
Deblina Sarkar's research focuses on developing autonomous, non-surgical nano-electronic implants that can integrate with biological tissue, potentially transforming treatments for neurological disorders. Current invasive brain implants are limited to less than 1% of patients due to high costs and significant risks.
These devices can autonomously recognize target disease regions in the brain and self-implant, delivering precise electrical stimulation. Challenges include miniaturizing devices to navigate the bloodstream and ensuring they can survive the body's immune response.
Sarkar's team has achieved significant progress in power conversion efficiency, allowing devices to operate effectively within the body. Preclinical results indicate that these nano-electronic devices can coexist with brain cells without causing damage, unlike traditional implants.
The technology presents unique advantages over existing brain implant methods, enabling non-surgical access to sensitive brain areas and the potential to treat aggressive brain cancers and chronic pain. Collaborations with hospitals have yielded promising results in inhibiting tumor growth.
Perspectives
Proponents of Nano-Electronics
- Highlight the potential of autonomous, non-surgical implants to revolutionize treatment for neurological disorders
- Emphasize the ability of these devices to self-implant and deliver precise stimulation without invasive procedures
Skeptics of Nano-Electronics
- Question the long-term viability and safety of nano-electronic devices in the human body
- Raise concerns about potential immune responses and the effectiveness of these devices in real-world conditions
Neutral / Shared
- Acknowledge the significant advancements in power conversion efficiency and biocompatibility of the devices
- Recognize the ongoing research and potential applications beyond neurological disorders
Metrics
10,000 times higher
power conversion efficiency of the devices
This efficiency allows for effective operation within the body
we showed that even at this subcellular size our device can have 10,000 times higher power conversion efficiency compared to other existing devices
777.9%
percentage of devices found in brain tissue after introduction
This high success rate indicates the potential effectiveness of the technology in targeting brain regions
in 777.9% of the time, these devices are actually in the brain
30 micrometers
resolution of stimulation achieved by the devices
This precision surpasses traditional large electrodes, enhancing treatment efficacy
the spatial resolution of stimulation that we achieved is around 30 micrometer
20 different cells, 18 different chemicals
analyzed in the blood
This analysis indicates the devices do not significantly alter blood chemistry
we analyzed 20 different cells, 18 different chemicals analyzed in the blood
1 inch inches
size of the hole required for Neuralink devices
This highlights the invasive nature of current brain implant technologies
A Neuralink device for example requires creating a 1 inch hole in the skull
12 to 15 months
typical survival time of patients diagnosed with brain cancer
This highlights the urgent need for innovative treatment options for aggressive brain cancers
A typical survival time of patients after they are diagnosed is only 12 to 15 months.
more than 85%
expected survival rate in patients with halted brain tumors
This high survival rate indicates a significant advancement in treatment options for brain cancer
this complete halting of brain tumor could lead to an expected survival of more than 85% in patients.
Key entities
Key developments
Phase 1
Deblina Sarkar's research focuses on developing autonomous, non-surgical nano-electronic implants that can integrate with biological tissue, potentially transforming treatments for neurological disorders. Current invasive brain implants are limited to less than 1% of patients due to high costs and significant risks.
- Deblina Sarkars research aims to create autonomous, non-surgical nano-electronic implants that can seamlessly integrate with biological tissue, potentially transforming the treatment landscape for neurological disorders affecting over three billion people worldwide
- Current invasive brain implants carry significant risks, including infection and exorbitant costs exceeding $100,000, which restricts their application to less than 1% of patients, underscoring the urgent need for safer alternatives
- Sarkar highlights the promise of miniature electronic devices capable of traversing the bloodstream, providing a safer and more effective approach to neuromodulation compared to traditional invasive methods
- The fusion of bioelectronics and neuroscience may lead to significant advancements in treating challenging conditions such as Alzheimers, depression, and paralysis, which are inadequately managed by existing therapies
Phase 2
Deblina Sarkar discusses the development of autonomous, surgery-free nano-electronic devices for brain treatment, which can self-implant and deliver precise stimulation. This technology aims to address the limitations of current invasive treatments for neurological disorders.
- Deblina Sarkar presents autonomous, surgery-free nano-electronic devices designed for self-implantation in the brain, aiming to overcome the limitations of current invasive treatments for neurological disorders
- The technology focuses on creating sub-cellular devices that can navigate the bloodstream, identify target disease areas, and deliver precise electrical stimulation, potentially transforming treatments for conditions like brain cancer and mental illnesses
- Challenges include miniaturizing devices to prevent disruption of normal bodily functions, ensuring wireless power capabilities, and addressing the immune response to foreign objects, especially when targeting the brain through the blood-brain barrier
- Sarkars team has made significant progress in power conversion efficiency, achieving devices that are 10,000 times more efficient than existing technologies of similar size, allowing effective operation within the body
- The fabrication of these devices takes place in clean room environments to avoid contamination, emphasizing the precision required in developing devices that are much smaller than a grain of rice
Phase 3
Deblina Sarkar's research focuses on developing autonomous, surgery-free nanoelectronic devices that can self-implant in targeted brain regions, addressing limitations of current invasive treatments for neurological disorders. These devices utilize engineered living cells to cross the blood-brain barrier, enabling precise neuromodulation without direct brain injections.
- Deblina Sarkars research aims to develop autonomous, surgery-free nanoelectronic devices capable of self-implantation in targeted brain regions, addressing the limitations of current invasive treatments for neurological disorders
- These devices utilize engineered living cells to cross the blood-brain barrier, enabling non-invasive treatment options without direct brain injections
- The hybrid technology allows for precise neuromodulation through wireless electromagnetic fields, achieving a spatial resolution of stimulation around 30 micrometers, which surpasses traditional large electrodes
- Preclinical results show that these nanoelectronic devices can coexist with brain cells without causing damage, in contrast to conventional implants that often result in cell death and inflammation
- The ability to autonomously locate and implant in the brain signifies a transformative advancement in treating conditions like brain cancer and other neurological diseases, potentially reshaping the future of brain-computer interfaces
Phase 4
Deblina Sarkar's research introduces autonomous, surgery-free nano-electronic devices designed for targeted brain treatment, overcoming limitations of traditional invasive implants. These biocompatible devices can cross the blood-brain barrier and deliver precise stimulation without triggering immune responses.
- Deblina Sarkars research focuses on creating autonomous, surgery-free nano-electronic devices that can self-implant in specific brain regions, addressing the challenges posed by traditional invasive implants
- These biocompatible sub-cellular devices are capable of crossing the blood-brain barrier, delivering targeted electrical stimulation without triggering immune responses or damaging surrounding brain tissue
- Preclinical studies indicate that the devices can maintain their position and functionality over time, suggesting their suitability for chronic applications while having minimal effects on overall health
- This technology presents significant advantages over existing brain implant methods, such as those employed by Neuralink, which involve invasive procedures and risks associated with accessing delicate brain areas
Phase 5
Deblina Sarkar presents a novel approach to treating neurological disorders through autonomous, surgery-free nano-electronic devices that can self-implant and deliver targeted stimulation. This technology aims to overcome the limitations of traditional invasive treatments, offering new hope for conditions like aggressive brain cancers and chronic pain.
- The technology allows for non-surgical brain implants that autonomously identify and target specific disease areas, addressing the limitations of traditional surgical methods
- This innovative approach offers new hope for treating aggressive brain cancers like glioblastoma and DIPG, which have historically had poor prognoses
- The capability to detect diffuse cancer sites that are not visible through imaging technologies creates unique treatment possibilities that surgical implants cannot achieve
- Research suggests the technology could be applied to a range of conditions, including chronic pain, Alzheimers disease, and movement disorders, showcasing its versatility
- Collaborations with institutions such as Mayo Clinic and Massachusetts General Hospital have enabled testing of bio-electric therapy on patient-derived tissues, yielding promising results in inhibiting tumor growth
Phase 6
Deblina Sarkar's research presents autonomous, non-surgical nano-electronic implants that can self-implant in targeted brain regions, offering new treatment options for neurological disorders. This technology aims to improve patient access to life-saving treatments by eliminating the need for invasive surgery.
- Deblina Sarkars research introduces autonomous, non-surgical nano-electronic implants capable of self-implantation in targeted brain regions, providing a novel solution for treating neurological disorders, including difficult-to-treat brain cancers
- Preclinical findings show that these devices can effectively halt tumor growth in brain cancer patients where conventional treatments have failed, potentially leading to improved survival rates
- The technology extends beyond brain applications, with potential for developing wireless pacemakers and health monitoring systems, facilitating early disease detection and human augmentation through synthetic electronic neurons
- Sarkars company, Cahira Technologies, plans to initiate clinical trials within three years, supported by recent seed funding of $35 million aimed at scaling development
- By removing the need for invasive surgery, this technology could enhance access to life-saving treatments for a wider patient population, potentially transforming healthcare delivery and costs